AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.99 |
Market Cap | 64.48M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.04 |
PE Ratio (ttm) | -49.87 |
Forward PE | n/a |
Analyst | Buy |
Ask | 2.07 |
Volume | 241,702 |
Avg. Volume (20D) | 726,406 |
Open | 2.06 |
Previous Close | 2.01 |
Day's Range | 1.98 - 2.06 |
52-Week Range | 1.16 - 5.15 |
Beta | undefined |
About RMTI
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stor...
Analyst Forecast
According to 2 analyst ratings, the average rating for RMTI stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 200.75% from the latest price.
Next Earnings Release
Analysts project revenue of $25.16M, reflecting a 13.88% YoY growth and earnings per share of 0.01, making a -50.00% decrease YoY.
3 months ago · businesswire.com
Rockwell Medical to Release Third Quarter 2024 Results on Monday, November 11, 2024WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its financial and operational results for the third quarter ended September 30, 2024 on Monday, November 1...